Stockscreener 앱 받기
16.91
0.94%
-0.16
전일 마감가:
$17.07
열려 있는:
$17.01
하루 거래량:
513.55K
Relative Volume:
1.36
시가총액:
$458.05M
수익:
$157.75M
순이익/손실:
$-29.73M
주가수익비율:
5.6555
EPS:
2.99
순현금흐름:
$-21.00M
1주 성능:
+5.56%
1개월 성능:
-14.55%
6개월 성능:
-47.78%
1년 성능:
-28.13%
1일 변동 폭
$16.20
$17.50
1주일 범위
$15.50
$18.09
52주 변동 폭
$14.93
$45.00
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
명칭
Arcturus Therapeutics Holdings Inc
전화
(858) 900-2660
주소
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
ARCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ARCT | 16.91 | 458.05M | 157.75M | -29.73M | -21.00M | 2.99 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-07-24 | 개시 | William Blair | Outperform |
| 2023-05-11 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | 재개 | Wells Fargo | Overweight |
| 2022-11-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-11-02 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-08-10 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-01-31 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-08-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-25 | 재개 | Goldman | Neutral |
| 2021-06-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-17 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | 개시 | Wells Fargo | Overweight |
| 2020-12-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-12-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | 다운그레이드 | ROTH Capital | Buy → Sell |
| 2020-12-08 | 재확인 | B. Riley Securities | Buy |
| 2020-12-07 | 재확인 | B. Riley Securities | Buy |
| 2020-10-26 | 개시 | Barclays | Overweight |
| 2020-10-06 | 개시 | Citigroup | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-30 | 재개 | ROTH Capital | Buy |
| 2020-07-16 | 개시 | Raymond James | Outperform |
| 2020-07-13 | 개시 | B. Riley FBR | Buy |
| 2020-06-09 | 다운그레이드 | WBB Securities | Buy → Hold |
| 2020-02-11 | 개시 | Robert W. Baird | Outperform |
| 2020-02-07 | 개시 | Guggenheim | Buy |
| 2020-02-06 | 개시 | Guggenheim | Buy |
| 2019-04-05 | 개시 | H.C. Wainwright | Buy |
| 2018-09-20 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | 개시 | Chardan Capital Markets | Buy |
모두보기
Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference - Yahoo Finance
Sumitomo Mitsui Trust Group Inc. Buys 712,650 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Avian Flu: FDA Authorizes Self-Replicating Vaccine Trial to Bill Gates-Backed Company, "Study Can Proceed" - presskit.it
Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data (NASDAQ:ARCT) - Seeking Alpha
Meiji Seika Pharma Invests in ARCALIS to Boost Japan's mRNA Vaccine Production | ARCT Stock News - StockTitan
Arcturus gains IND clearance for H5N1 influenza sa-RNA vaccine candidate - BioWorld Online
Possible Signal As Arcturus Therapeutics Holdings Insiders Sell US$1.6m In Stock - Simply Wall St
Another Avian Influenza mRNA Vaccine Candidate Advances - Precision Vaccinations
Arcturus Therapeutics Holdings Inc. Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial - Marketscreener.com
What is HC Wainwright's Estimate for ARCT FY2028 Earnings? - MarketBeat
Arcturus Therapeutics’ (ARCT) Buy Rating Reiterated at HC Wainwright - Defense World
Earnings call: Arcturus Therapeutics reported a net loss of $6.9 million - Investing.com Australia
Arcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2024 Earnings Call Transcript - Insider Monkey
Nikko Asset Management Americas, Inc. Expands Stake in Arcturus Therapeutics Holdings Inc. - GuruFocus.com
Arcturus Therapeutics (NASDAQ:ARCT) Receives "Buy" Rating from HC Wainwright - MarketBeat
ARK Investment Management LLC Has $48.77 Million Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $71.40 Average Target Price from Brokerages - Defense World
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call - GuruFocus.com
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call Highlights: Strategic Advances ... - Yahoo Finance UK
Arcturus Therapeutics Reports Q3 2024 Financial Results and Milestones - TipRanks
Arcturus Therapeutics Holdings Inc earnings beat by $0.31, revenue fell short of estimates - Investing.com
ARCTArcturus Therapeutics Holdings Inc. Latest Stock News & Market Updates - StockTitan
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Arcturus Therapeutics: Q3 Earnings Snapshot - Marketscreener.com
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress - Business Wire
Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect - MSN
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Repor - GuruFocus.com
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Sumitomo Mitsui Trust Group, Inc. Expands Investment in Arcturus Therapeutics Holdings Inc. - GuruFocus.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Empire Life Investments Inc. Purchases New Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics (ARCT) Scheduled to Post Earnings on Thursday - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Shares Pass Below Two Hundred Day Moving AverageHere's Why - MarketBeat
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024 - Business Wire
Arcturus Therapeutics (ARCT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Arcturus falls after detailed Phase 1 data for cystic fibrosis therapy - MSN
Leerink Partners Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Outperform Recommendation - MSN
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 6.1%What's Next? - MarketBeat
Investing in Arcturus Therapeutics Holdings (NASDAQ:ARCT) five years ago would have delivered you a 76% gain - Yahoo Finance
8,235 Shares in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Acquired by SG Americas Securities LLC - Defense World
A slow start for self-amplifying mRNA vaccines - Yahoo Finance
Vontobel Holding Ltd. Trims Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 5.8% Following Insider Selling - MarketBeat
AQR Capital Management LLC Has $285,000 Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Insider Sale at Arcturus Therapeutics Holdings Inc (ARCT) - GuruFocus.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Pad Chivukula Sells 12,000 Shares - MarketBeat
Arcturus Therapeutics executive sells $249,121 in stock By Investing.com - Investing.com Canada
Arcturus Therapeutics executive sells $249,121 in stock - Investing.com India
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest Update - MarketBeat
Arcturus Therapeutics Holdings Inc (ARCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
2.08%
자본화:
|
볼륨(24시간):